Referenser
ACR Hotline: Abatacept and Rituximab. May 2006.
Aksoy S, Abali H, Kilickap S, et al. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006;28:211-214.
Alvarez C, Brown B, Aristides M, et al. Cost analysis of introducing rituximab as new treatment approach for rheumatoid arthritis: the Spanish perspective. Ann Rheum Dis 2006;65(Suppl II):273.
Breedveld FC, Agarwal S, Yin M, et al. Relationship between clinical response, rituximab pharmacokinetics, and peripheral B cell levels in rheumatoid arthritis. Arthritis Rheum 2005;52 (Abstract 279).
Brown B, De Vita S, Giuliani G, et al. Pharmacoeconomic model using microsimulation to assess impact of providing rituximab for treatment of rheumatoid arthritis: the Italian perspective. Ann Rheum Dis 2006;65(Suppl II):277.
Burmester GR, Ruderman EM, Durez P, et al. Oral glucocorticoids have no impact on the efficacy or safety profile of rituximab in rheumatoid arthritis patients with inadequate response to TNF inhibitors (REFLEX study). Ann Rheum Dis 2006;65(Suppl II):180.
Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-446.
Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806.
Cohen S, Emery P, Greenwald M, et al. Prolonged efficacy of rituximab in rheumatoid arthritis patients with inadequate response to one or more TNF inhibitors: 1-year follow-up of a subset of patients receiving a single course in a controlled trial (REFLEX study). Ann Rheum Dis 2006;65(Suppl II):183.
De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenic role of B cells. Arthritis Rheum 2002;46:2029-2033.
De Vita S, Furst DE, Gomez Reino JJ, et al. Efficacy of rituximab treatment and further courses of treatment in patients with rheumatoid arthritis is not dependent on rheumatoid factor seroreversion. Ann Rheum Dis 2006;65(Suppl II):186.
Edwards JC, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 1998;37:126-130.
Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-211.
Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581.
Edwards JC, Leandro MJ, Cambridge G. Repeated B lymphocyte depletion therapy in rheumatoid arthritis: 5 year follow-up. Arthritis Rheum 2005;52 (Abstract 270).
Emery P, Fleischmann RM, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400.
Emery P, Fleischmann R, Martin-Mola E, et al. Prolonged efficacy of rituximab in rheumatoid arthritis patients with an inadequate response to methotrexate: 1 year follow-up of a subset of patients receiving a single course in a controlled trial (DANCER trial). Ann Rheum Dis 2006;65(Suppl II):190.
Emery P, Furst DE , Ferraccioli G, et al. Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs. Ann Rheum Dis 2006;65(Suppl II):58.
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361.
Fleischmann RM, Pavelka K, Baldassare AR, et al. Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis. Arthritis Rheum 2005;52(Abstract 264).
Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-3908.
Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol 2002;29:105-112.
Hirano T. Revival of the autoantibody model in rheumatoid arthritis. Nat Immunol 2002;3:342-344.
Keystone E, Emery P, Peterfy CG, et al. Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study). Ann Rheum Dis 2006;65(Suppl II):58.
Keystone E, Fleischmann R, Emery P, et al. Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 2006;65(Suppl II):323.
Kremer JM, Tony H, Tak PP, et al. Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 2006;65(Suppl II):326.
Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-888.
Lewis G, Porter D, Brown B, et al. Economic consequences of providing rituximab as a new therapeutic option for rheumatoid arthritis in the UK. Ann Rheum Dis 2006;65(Suppl II):283.
Lund FE, Garvy BA, Randall TD, Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005;8:25-54. MabThera® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd, 2006.
Magrini F, Grunert VP, Eberl H, et al. Correlation of serum biochemical markers with response to treatment of rheumatoid arthritis with rituximab. Arthritis Rheum 2005;52(Abstract 1461).
Moreland L. Unmet needs in rheumatoid arthritis. Arthritis Res Ther 2005;7(Suppl 3):S2-S8.
Rituxan® Prescribing Information.
Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-3061.
Roitt I, Brostoff J, Male D. Immunology. London, UK: Mosby, 2001.
Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-3826.
Schach S, Rubbert A, Diamantopoulos A, et al. Cost implications of introducing rituximab as a new treatment modality for rheumatoid arthritis in Germany. Ann Rheum Dis 2006;65(Suppl II):600.
Sell S, Max EE. Immunology, Immunopathology, and Immunity. American Society Microbiology, 2001.
Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003;62(Suppl. 2):ii55-ii59. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003;5(Suppl 4):S1-S6.
Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003;5(Suppl 4):S1-S6.
Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-1492.
Tak PP, Mease P, Bombardieri S, et al. Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors. Ann Rheum Dis 2006;65(Suppl II):503.
Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-1080.
van Vollenhoven RF, Emery P, et al. Safety of rituximab in rheumatoid arthritis: results of a pooled analysis. Ann Rheum Dis 2006;65(Suppl II):332.
van Vollenhoven RF, Schechtman J, Szczepanski LJ, et al. Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis (RA): results from the dose-ranging assessment international clinical evaluation of rituximab in RA (DANCER) study. Ann Rheum Dis 2005;64(Suppl III):1405.
van Vollenhoven RF, Cohen S, Pavelka K, et al. Response to rituximab in patients with rheumatoid arthritis is maintained by repeat therapy: results of an open-label trial. Ann Rheum Dis 2006;65(Suppl II):510.
van Vollenhoven RF, Emery P, Bingham C, et al. Safety of rituximab in rheumatoid arthritis: results of a pooled analysis. Ann Rheum Dis 2006;65(Suppl II):332.
Weitz IC. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol 2005;78:138-141.
Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-3834.
Zvaifler NJ. The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 1973;16:265-336.